A5035332995- Iron Metabolism and Disorders
- Poxvirus research and outbreaks
- Erythropoietin and Anemia Treatment
- Hemoglobinopathies and Related Disorders
- Immunotherapy and Immune Responses
- Potassium and Related Disorders
- Restless Legs Syndrome Research
- Parkinson's Disease Mechanisms and Treatments
- Transgenic Plants and Applications
- Dermatology and Skin Diseases
- Immunodeficiency and Autoimmune Disorders
- Virus-based gene therapy research
- Bacillus and Francisella bacterial research
- SARS-CoV-2 and COVID-19 Research
- Dialysis and Renal Disease Management
- Herpesvirus Infections and Treatments
- vaccines and immunoinformatics approaches
- Pharmaceutical studies and practices
- Sleep and Wakefulness Research
- Trace Elements in Health
- Monoclonal and Polyclonal Antibodies Research
- Eosinophilic Esophagitis
- Dysphagia Assessment and Management
Vifor Pharma (Switzerland)
2014-2017
Bavarian Nordic (Germany)
2009-2016
Liverpool Hospital
2016
UNSW Sydney
2016
Hospital Alemán
2016
National University Hospital
2016
Kardiologie Frankfurt-Sachsenhausen
2016
Crohn's and Colitis UK
2016
Vifor Pharma (Germany)
2012-2015
Background. First- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new vaccine is needed to protect this population the context of biodefense preparedness. The focus study was compare safety immunogenicity a replication-deficient, highly attenuated modified vaccinia Ankara (MVA) HIV-infected healthy subjects. Methods. An open-label, controlled Phase II trial conducted at 36 centers United States Puerto Rico for...
Background. Human immunodeficiency virus (HIV)–infected persons are at higher risk for serious complications associated with traditional smallpox vaccines. Alternative vaccines an improved safety profile would address this unmet medical need. Methods. The and immunogenicity of modified vaccinia Ankara (MVA) was assessed in 91 HIV-infected adult subjects (CD4+ T-cell counts, ≥350 cells/mm3) 60 uninfected volunteers. primary objectives were to evaluate the MVA subjects. As a measure potential...
Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine humans, showed favorable safety and immunogenicity profile healthy volunteers.This Phase II study compared the of MVA enrolling groups 350 subjects AD (SCORAD ≤ 30) 282 subjects.Subjects were vaccinated twice MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters,...
Background Modified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of (MVA) was assessed in 56–80 years old population. Methods MVA with virus titer 1 x 108 TCID50/dose administered via subcutaneous injection to year vaccinia-experienced subjects (N = 120). Subjects received either two injections (MM group) or one Placebo (PM four weeks apart. Safety...
The treatment of iron deficiency anemia in children with inflammatory bowel disease is a particular challenge and often insufficient. Absorption orally given may be impaired by intestinal inflammation oral aggravate inflammation. This retrospective study the first to describe use intravenous ferric carboxymaltose (FCM) pediatric setting.All subjects who had received at least one dose FCM intravenously observation period were included this analysis data collected for up 3 months post last...
Abstract Background : Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for treatment iron‐deficient nonanemic patients. Methods Patients with moderate to severe serum ferritin < 75 μg/L (or 75‐300 transferrin saturation 20%) were randomized (1000 mg iron) or placebo. Mean change difference between International Restless Legs Syndrome Severity Scale...
Background. Anemia is a common condition in the elderly and significant risk factor for increased morbidity mortality, reducing not only functional capacity mobility but also quality of life. Currently, few data are available regarding anemia hospitalized geriatric patients. Our retrospective study investigated epidemiology causes 405 Methods. Data analysis was performed using laboratory parameters determined during routine hospital admission procedures (hemoglobin, ferritin, transferrin...
Background Conventional smallpox vaccines based on replicating vaccinia virus (VV) strains (e.g. Lister Elstree, NYCBOH) are associated with a high incidence of myo-/pericarditis, severe inflammatory cardiac complication. A new vaccine candidate non-replicating Modified Vaccinia Ankara (MVA) poxvirus has been assessed for safety in large placebo-controlled clinical trial. Methods Cardiac one and two doses MVA compared to placebo was 745 healthy subjects. Vaccinia-naïve subjects received...
Current iron supplementation practice in geriatric patients is erratic and lacks evidence-based recommendations. Despite potential benefits this population, intravenous often withheld due to concerns regarding pharmacy expense, perceived safety issues, doubts efficacy elderly patients. This retrospective, observational cohort study aimed evaluate the of ferric carboxymaltose (FCM, Ferinject) aged >75 years with deficiency anaemia (IDA). Within a twelve-month data extraction period, charts...
Einleitung: Anämien stellen die häufigste Gruppe von extraintestinalen Manifestationen bei CED-Patienten dar. Dabei spielen Eisenmangelanämien und aufgrund chronischer Entzündung Patienten mit Colitis ulcerosa (CU) ursächlich größte Rolle. Je nach Definition, Zeitpunkt Studienpopulation wird eine Prävalenz 16 – 74% beschrieben. Flächendeckende Daten aus Schwerpunktpraxen zu Prävalenz, Management Verlauf der Anämie CU-Patienten in Deutschland liegen bisher nicht vor.
e19561 Background: Controlled studies showed that intravenous iron can improve hemoglobin (Hb) levels and decrease the need for erythropoiesis-stimulating agents (ESAs) blood transfusions in anemic cancer patients. This observational study provides data on effectiveness safety of ferric carboxymaltose (FCM) routine treatment anemia Methods: 642 patients (≥18 years) with deficiency were registered from Dec 2008 to Jul 2010 at 73 German hematology/oncology practices. FCM was administered...